Phastar to Provide Pro Bono Aid to Medicines Development for Global Health
Support to focus on two double-blind Phase IIIb clinical studies in the Democratic Republic of Congo and Cote d’Ivoire.
Phastar, a biometrics contract research organization (CRO), announced that it will be providing pro bono support to Medicines Development for Global Health (MDGH), a nonprofit focused on the development of medicines for neglected diseases primarily affecting people living in low- and middle-income countries. As part of Phastar’s assistance, MDGH will have access to the company’s biometrics experts during two large double-blind Phase IIIb clinical studies in the Democratic Republic of Congo and Cote d’Ivoire. According to a company release, one trial will be focused on evaluating the safety of moxidectin and the second is evaluating repeat single dosing compared with ivermectin in individuals living in onchocerciasis (river blindness) endemic areas.
At Phastar, we have the expertise and the resources to make a meaningful difference and to deliver on our mission to improve human health. As a B Corp organization, we strive to be a force for good, and one of our strategic objectives is to lead the CRO industry in corporate social responsibility,” said Graham Clark, CEO, Phastar. “The Phastar Cares Scheme, which offers free access to our statisticians, data scientists, data managers, and programmers, is an important part of that commitment. We are proud to be in a position to help MDGH on their mission to eradicate onchocerciasis.”
Reference: Phastar Offers Pro Bono Support to Medicines Development for Global Health. Phastar. October 26, 2023. Accessed October 27, 2023. https://phastar.com/resources/news/318-phastar-offers-pro-bono-support-to-medicines-development-for-global-health
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
